Skip to main content
. 2026 Oct 29;17:1947706. doi: 10.3389/fpsyt.2026.1947706

Table 6.

Adverse effects by antidepressant agent.

Antidepressant Patients, n Any adverse effect, all patients, n/N (%) Any adverse effect, monotherapy, n/N (%) Any adverse effect, concomitant treatment, n/N (%) Most frequent adverse effects, n
Fluoxetine 313 56/313 (17.9) 26/213 (12.2) 30/100 (30.0) Sedation (23), Weight gain (15), Bruxism (9)
Sertraline 222 46/222 (20.7) 4/101 (4.0) 42/121 (34.7) Sedation (29), Weight gain (25), Loss of appetite (4)
Mirtazapine 44 25/44 (56.8) 9/14 (64.3) 16/30 (53.3) Weight gain (22), Sedation (15), Loss of appetite (1)
Escitalopram 41 6/41 (14.6) 1/13 (7.7) 5/28 (17.9) Sedation (3), Weight gain (3), Akathisia (1)
Imipramine 21 5/21 (23.8) 5/18 (27.8) 0/3 (0.0) Sedation (4), Palpitations (1), Dry mouth (1)
Paroxetine 16 8/16 (50.0) 1/4 (25.0) 7/12 (58.3) Weight gain (6), Sedation (4), Sexual dysfunction (1)
Citalopram 7 1/7 (14.3) 0/4 (0.0) 1/3 (33.3) Sedation (1)
Venlafaxine 6 2/6 (33.3) – 2/6 (33.3) Sedation (2), Weight gain (1)
Duloxetine 3 0/3 (0.0) 0/2 (0.0) 0/1 (0.0) –
Fluvoxamine 2 1/2 (50.0) – 1/2 (50.0) Sedation (1), Weight gain (1)
Trazodone 1 1/1 (100.0) – 1/1 (100.0) Weight gain (1)

Each row includes all patients who received the agent (27 patients received two antidepressants and are counted under both agents). Adverse effects occurring during concomitant treatment may be attributable to the co-prescribed agent. Descriptive data; no statistical comparison was made between agents because of small numbers.